metoclopramide

(redirected from Metozolv ODT)
Also found in: Medical.

met·o·clo·pra·mide

 (mĕt′ə-klō′prə-mīd′)
n.
A dopamine antagonist, C14H22ClN3O2, that stimulates movement in the upper gastrointestinal tract, used in its hydrochloride form to treat nausea, gastroesophageal reflux, and diabetic gastroparesis.

[French métoclopramide : mét(h)-, meth- + o(xy)-, oxy- + c(h)lo(ro)-, chloro- + pr(ocaïn)amide, procainamide, a drug used to treat arrhythmia (procaïne, procaine + amide, amide).]
Translations

metoclopramide

n metoclopramida
Mentioned in ?
References in periodicals archive ?
For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV ODT, please visit www.
For full prescribing information and important safety information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV ODT, on Salix products, please visit www.
During 2009 we expanded our commercial portfolio with the launch of APRISO in March and the launch of METOZOLV ODT in November.
This guidance incorporates the recognition of METOZOLV ODT revenue based on prescription pull-through.
We believe METOZOLV ODT again demonstrates our commitment to provide innovative products to meet the unmet GI treatment needs of physicians and patients.
METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
METOZOLV ODT, which rapidly* melts on the tongue, gives these patients a new choice that may be more convenient than traditional metoclopramide tablets.
Based on the facts and circumstances associated with the anticipated launch of METOZOLV ODT we currently intend to recognize METOZOLV ODT revenue based on prescription pull-through rather than product shipment or sell-in to wholesalers.
We plan to update 2009 revenue and loss per share guidance if and when METOZOLV ODT is approved and launched to physicians.
We will update 2009 revenue and loss per share guidance if METOZOLV ODT is approved and launched to physicians.